Bio-Path Holdings Presents BP1002 Data at 2021 American Association for Cancer Research Annual Meeting
April 12 2021 - 7:00AM
Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company
leveraging its proprietary DNAbilize® antisense RNAi nanoparticle
technology to develop a portfolio of targeted nucleic acid cancer
drugs, today announces the presentation of a poster highlighting
preclinical BP1002 data at the 2021 American Association for Cancer
Research (AACR) Annual Meeting.
The poster, titled “The combination of liposomal
Bcl-2 antisense oligonucleotide (BP1002) with decitabine is
efficacious in venetoclax-resistant cells,” was presented virtually
by Dr. Maria Gagliardi, Research Scientist at Bio-Path
Holdings.
"We are particularly pleased to have these
preclinical results of the BP1002 plus decitabine combination
against venetoclax-resistant cells highlighted in a poster before
an audience of the world’s leading cancer researchers at this
important scientific meeting," stated Peter Nielsen, President and
Chief Executive Officer of Bio-Path Holdings. “We look forward to
filing a second Investigational New Drug (IND) application for
BP1002 and to initiating a clinical study in combination with
decitabine in acute myeloid leukemia (AML) patients who have
relapsed from venetoclax-based treatments.”
Venetoclax, an FDA-approved Bcl-2 inhibitor, is
indicated for hematologic malignancies. However, venetoclax
resistance among these AML patients is a growing problem. A recent
study found that AML patients who had relapsed from frontline
venetoclax-based treatment were also resistant to salvage therapy
and had a median survival of less than 3 months1. Thus, novel
treatment approaches for these most vulnerable patients are
urgently needed.
BP1002 targets the protein Bcl-2, which is
responsible for driving cell survival in up to 60% of all cancers.
High expression of Bcl-2 has been correlated with poor prognosis
for patients diagnosed with AML. Prior preclinical studies have
shown BP1002 to be a potent inhibitor against the Bcl-2 target, and
the Company believes that its benign safety profile should enable
BP1002 combination therapy with approved agents.
The data presented in the AACR poster show that
venetoclax-resistant cells are sensitive to the inhibitory effects
of BP1002 combined with decitabine, suggesting that this
combination is a potential treatment for patients who have relapsed
from frontline venetoclax-based therapies.
About Bio-Path Holdings,
Inc.
Bio-Path is a biotechnology company developing
DNAbilize®, a novel technology that has yielded a pipeline of RNAi
nanoparticle drugs that can be administered with a simple
intravenous transfusion. Bio-Path’s lead product candidate,
prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2
study for the treatment of blood cancers and prexigebersen-A, a
drug product modification of prexigebersen, is under consideration
by the FDA to commence Phase 1 studies in solid tumors. This is
followed by BP1002, targeting the Bcl-2 protein, where it is being
evaluated in a Phase 1 study in advanced lymphoma and chronic
lymphocytic leukemia patients.
For more information, please visit the Company's
website at http://www.biopathholdings.com.
1) Maiti et al. Haematologica, 2021,
106(3):894-898.
Forward-Looking Statements
This press release contains forward-looking
statements that are made pursuant to the safe harbor provisions of
the federal securities laws. These statements are based on
management's current expectations and accordingly are subject to
uncertainty and changes in circumstances. Any express or implied
statements contained in this press release that are not statements
of historical fact may be deemed to be forward-looking statements.
Any statements that are not historical facts contained in this
release are forward-looking statements that involve risks and
uncertainties, including the impact, risks and uncertainties
related to COVID-19 and actions taken by governmental authorities
or others in connection therewith, Bio-Path’s ability to raise
needed additional capital on a timely basis in order for it to
continue its operations, Bio-Path's ability to have success in the
clinical development of its technologies, the timing of enrollment
and release of data in such clinical studies and the accuracy of
such data, limited patient populations of early stage clinical
studies and the possibility that results from later stage clinical
trials with much larger patient populations may not be consistent
with earlier stage clinical trials, the maintenance of intellectual
property rights, that patents relating to existing for future
patent applications will be issued or that any issued patents will
provide meaningful protection of our drug candidates, risks
relating to maintaining Bio-Path's listing on the Nasdaq Capital
Market and such other risks which are identified in Bio-Path's most
recent Annual Report on Form 10- K, in any subsequent quarterly
reports on Form 10-Q and in other reports that Bio-Path files with
the Securities and Exchange Commission from time to time. These
documents are available on request from Bio-Path Holdings or at
www.sec.gov. Bio-Path disclaims any intention or obligation to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Contact
Information: Investors
Will O’ConnorStern Investor Relations
212-362-1200will@sternir.com
Doug Morris Investor Relations Bio-Path
Holdings, Inc. 832-742-1369
Bio Path (NASDAQ:BPTH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bio Path (NASDAQ:BPTH)
Historical Stock Chart
From Apr 2023 to Apr 2024